PDS Biotechnology Corporation

XNAS

Last traded price · USD

$1.27

−9.93%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 06:26 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $1.41
Volume: 4.6M
Day's high: —
Day's low: —

In brief

PDS Biotechnology Corporation is a US-listed company listed on Nasdaq, valued at about $92M.
Its shares closed at $1.30 on 4 Nov 2026, up 46.3% over the past year.
From India you can buy PDSB in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy PDS Biotechnology Corporation (PDSB) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole PDSB share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade PDSB options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Ahead of SPY over 1 year
1 month: +24.4% (SPY −1.6%). 3 months: +78.9% (SPY −0.4%). 1 year: +46.3% (SPY +13.6%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: PDSB, SPY · as of 4 Nov 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $1.30 was 49.6% above its 50-day average ($0.87) and 55.6% above its 200-day average ($0.84). It has closed above the 200-day for 23 sessions, since 5 Oct 2026. The 50-day average crossed above the 200-day on 3 Nov 2026, 1 session ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Light volume: 0.5× its 30-session average on 4 Nov 2026
4 Nov 2026 volume of 4.6M shares was 0.5× the average of the 30 sessions before it (10.2M), as the price fell 7.8%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026
69% of the way up its 52-week range
Closed at $1.30 on 4 Nov 2026: 27.4% below the 52-week high of $1.79 (13 Oct 2026) and 566.0% above the low of $0.20 (19 Aug 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Short interest at 3.2% of shares outstanding
3.4M shares were sold short at the 15 Oct 2026 settlement, 3.2% of the 105.0M shares outstanding; covering them would take 1.0 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+24.4%

6 months+22.6%

1 year+46.3%

5 years−89.1%

Newswire

About

PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.

Website

Notable moves

October 5, 2026
+60.32%
September 16, 2026
+69.25%
August 11, 2026
−64.87%

Newswire

About

Website

Notable moves

October 5, 2026
+60.32%
September 16, 2026
+69.25%
August 11, 2026
−64.87%

PDS Biotechnology Corporation

XNAS

Last traded price · USD

$1.27

−9.93%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 06:26 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $1.41
Volume: 4.6M
Day's high: —
Day's low: —

In brief

PDS Biotechnology Corporation is a US-listed company listed on Nasdaq, valued at about $92M.
Its shares closed at $1.30 on 4 Nov 2026, up 46.3% over the past year.
From India you can buy PDSB in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy PDS Biotechnology Corporation (PDSB) shares from India?

Do I need the price of a whole PDSB share to invest?

How much can I invest in US stocks in a year?

Can I trade PDSB options or futures?

Insights

Quotes run fifteen minutes behind.

Ahead of SPY over 1 year
1 month: +24.4% (SPY −1.6%). 3 months: +78.9% (SPY −0.4%). 1 year: +46.3% (SPY +13.6%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: PDSB, SPY · as of 4 Nov 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $1.30 was 49.6% above its 50-day average ($0.87) and 55.6% above its 200-day average ($0.84). It has closed above the 200-day for 23 sessions, since 5 Oct 2026. The 50-day average crossed above the 200-day on 3 Nov 2026, 1 session ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Light volume: 0.5× its 30-session average on 4 Nov 2026
4 Nov 2026 volume of 4.6M shares was 0.5× the average of the 30 sessions before it (10.2M), as the price fell 7.8%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026
69% of the way up its 52-week range
Closed at $1.30 on 4 Nov 2026: 27.4% below the 52-week high of $1.79 (13 Oct 2026) and 566.0% above the low of $0.20 (19 Aug 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Short interest at 3.2% of shares outstanding
3.4M shares were sold short at the 15 Oct 2026 settlement, 3.2% of the 105.0M shares outstanding; covering them would take 1.0 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+24.4%

6 months+22.6%

1 year+46.3%

5 years−89.1%

Newswire

About

Website

Notable moves

October 5, 2026
+60.32%
September 16, 2026
+69.25%
August 11, 2026
−64.87%

Newswire

About

Website

Notable moves

October 5, 2026
+60.32%
September 16, 2026
+69.25%
August 11, 2026
−64.87%

PDS Biotechnology Corporation

PDS Biotechnology Corporation in brief

Ahead of SPY over 1 year

Above its 50- and 200-day averages

Light volume: 0.5× its 30-session average on 4 Nov 2026

69% of the way up its 52-week range

Short interest at 3.2% of shares outstanding

PDS Biotechnology Corporation

PDS Biotechnology Corporation in brief

Ahead of SPY over 1 year

Above its 50- and 200-day averages

Light volume: 0.5× its 30-session average on 4 Nov 2026

69% of the way up its 52-week range

Short interest at 3.2% of shares outstanding